A1Lead compound
Depside · Umbilicaria hirsuta
The best-characterised compound in the portfolio. Published work reports ROS production,
apoptosis and modulation of Akt, Erk1/2 and p38 MAPK in HeLa cells, with a validated isolation
protocol giving high-purity material.
- Antiproliferative screening
- ROS / oxidative stress
- Apoptosis
- HeLa model
- Evidence
- Peer-reviewed 2019 · mechanistic dataset
- Stage
- Pilot-ready · licensing open
- Indicative
- € 8 000 – 35 000negotiable by scope and application
A2
Depsidone · Hypogymnia physodes
The strongest radical scavenger in our comparative metabolite study — and the comparison was
made per mole rather than per unit weight. That distinction matters when you translate a screening
result into a formulation dose.
- Antioxidant discovery
- Cosmetic actives
- Nutraceuticals
- Evidence
- Peer-reviewed 2022 · DPPH + superoxide
- Stage
- Pilot-ready · licensing open
- Indicative
- € 5 000 – 25 000negotiable by scope and application
A3
Depside · Reference metabolite
A widely cited lichen compound with repeatedly published bioactivity, included in both of our
screening studies. A dependable reference compound and panel anchor for antiproliferative,
antioxidant and antimicrobial work.
- Cytotoxicity
- Redox modulation
- Reference standard
- Evidence
- Peer-reviewed 2022 & 2023
- Stage
- Pilot-ready · licensing open
- Indicative
- € 4 000 – 22 000negotiable by scope and application
A4
Depsidone · Hypogymnia physodes
Present in both of our published panels, with antioxidant and antiproliferative activity
reported in 2D and 3D models. A natural comparator when you want to benchmark a candidate
against gyrophoric acid within one experimental system.
- Antioxidant
- Antiproliferative
- Panel candidate
- Evidence
- Peer-reviewed 2022 & 2023
- Stage
- Pilot-ready · licensing open
- Indicative
- € 5 000 – 25 000negotiable by scope and application
A5
Depside · Evernia prunastri
Isolated from Evernia prunastri and tested in DPPH and superoxide anion scavenging
assays in our 2022 comparative study, then carried into the 2023 multi-compound panel. Clear
positioning for cosmetic and nutraceutical antioxidant discovery.
- Natural antioxidant
- Cosmetics
- Nutraceuticals
- Evidence
- Peer-reviewed 2022 & 2023
- Stage
- Pilot-ready · licensing open
- Indicative
- € 4 000 – 20 000negotiable by scope and application
A6Research use only
Dibenzofuran · Benchmark compound
The standard reference metabolite for benchmarking cytotoxicity and antioxidant assays, and a
control compound in multi-metabolite panels. Supplied for research use only — significant
toxicological caution is required before any consumer positioning.
- Benchmark assay
- Research use
- Toxicological caution
- Evidence
- Peer-reviewed 2022 (comparative)
- Stage
- Pilot-ready · RUO material
- Indicative
- € 3 000 – 18 000negotiable by scope and application
A7Fastest entry point
Standardised crude / semi-purified extracts · 5–10 species
The quickest way to see what lichen chemistry can do for your pipeline. Panels of
Pseudevernia furfuracea, Lobaria pulmonaria, Cetraria islandica,
Umbilicaria hirsuta and related species, with HPLC/LC-MS profiling plus antioxidant,
antimicrobial and cell viability assays. You receive a shortlist of active candidates with data.
- Discovery screening
- Multi-species panel
- Antiproliferative
- Antimicrobial
- Antioxidant
- Lead fractionation
- Evidence
- Peer-reviewed 2023 · profiling data
- Stage
- Pilot-ready · 8–12 weeks
- Indicative
- € 8 000 – 40 000lead isolation quoted individually
